This paradigm is best exemplified in BRCA1 and BRCA2 pathogenic variant carriers where knowledge of the function of these genes led to the development of poly (ADP-ribose) polymerase (PARP) inhibition as a novel therapy for the treatment of breast cancers [70]. Here, BRCA1 is linked to breast carcinoma.